An award-winning journalist, Derrick has written extensively about user fee negotiations, the FDA budget, FDA travel restrictions and drug advertising compliance. He also was part of the Pink Sheet team covering FDA's first biosimilar advisory committee meetings.
When he's not following FDA, Derrick is keeping close tabs on Indiana Hoosiers basketball.
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Derrick Gingery
Idea suggested during 'Great Debate,' but agency official says no adlibbing is allowed in the regulations.
FDA wants to publicize some aspects of designs accepted into pilot, which might discourage industry participation.
Thanks in large part to new elemental impurities requirements, ANDA approvals are behind the pace needed to beat 2017’s record.